MX2021003687A - Procesos y compuestos intermediarios para preparar piridona amidas útiles como moduladores de canales de sodio para el tratamiento de dolor. - Google Patents

Procesos y compuestos intermediarios para preparar piridona amidas útiles como moduladores de canales de sodio para el tratamiento de dolor.

Info

Publication number
MX2021003687A
MX2021003687A MX2021003687A MX2021003687A MX2021003687A MX 2021003687 A MX2021003687 A MX 2021003687A MX 2021003687 A MX2021003687 A MX 2021003687A MX 2021003687 A MX2021003687 A MX 2021003687A MX 2021003687 A MX2021003687 A MX 2021003687A
Authority
MX
Mexico
Prior art keywords
sodium channels
modulators
pyridone
pyridone amides
pharmaceutically acceptable
Prior art date
Application number
MX2021003687A
Other languages
English (en)
Inventor
Sara Sabina Hadida-Ruah
Brian Richard Bear
Vijayalaksmi Arumugam
Corey Anderson
Iuliana Luci Asgian
Andreas P Termin
Jr James Philip Johnson
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2021003687A publication Critical patent/MX2021003687A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/24—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Ink Jet (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se relaciona con compuestos de piridona amida de fórmula I y I´ o sales farmacéuticamente aceptables de los mismos, útiles como inhibidores de canales de sodio: (ver Fórmulas) I I´ La invención también proporciona composiciones farmacéuticamente aceptables que comprenden los compuestos de la invención y métodos de uso de las composiciones en el tratamiento de varios trastornos, incluyendo el dolor.
MX2021003687A 2013-01-31 2014-01-29 Procesos y compuestos intermediarios para preparar piridona amidas útiles como moduladores de canales de sodio para el tratamiento de dolor. MX2021003687A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361759059P 2013-01-31 2013-01-31
PCT/US2014/013652 WO2014120808A1 (en) 2013-01-31 2014-01-29 Pyridone amides as modulators of sodium channels

Publications (1)

Publication Number Publication Date
MX2021003687A true MX2021003687A (es) 2023-01-25

Family

ID=50073531

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021003687A MX2021003687A (es) 2013-01-31 2014-01-29 Procesos y compuestos intermediarios para preparar piridona amidas útiles como moduladores de canales de sodio para el tratamiento de dolor.
MX2015009602A MX2015009602A (es) 2013-01-31 2014-01-29 Piridona amidas como moduladores de canales de sodio.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2015009602A MX2015009602A (es) 2013-01-31 2014-01-29 Piridona amidas como moduladores de canales de sodio.

Country Status (34)

Country Link
US (6) US9051270B2 (es)
EP (3) EP3865475A1 (es)
JP (4) JP6389194B2 (es)
KR (2) KR102295748B1 (es)
CN (2) CN105026373B (es)
AP (1) AP2015008633A0 (es)
AR (1) AR094667A1 (es)
AU (3) AU2014212509B2 (es)
BR (1) BR112015018289A2 (es)
CA (1) CA2898866C (es)
CL (1) CL2015002147A1 (es)
CY (1) CY1119163T1 (es)
DK (2) DK2953931T3 (es)
ES (2) ES2857687T3 (es)
GE (2) GEP20207177B (es)
HK (2) HK1217693A1 (es)
HR (2) HRP20170787T1 (es)
HU (2) HUE033370T2 (es)
IL (1) IL240195B (es)
LT (2) LT3239134T (es)
MX (2) MX2021003687A (es)
NZ (2) NZ710270A (es)
PE (2) PE20151781A1 (es)
PH (1) PH12015501661B1 (es)
PL (2) PL2953931T3 (es)
PT (2) PT2953931T (es)
RS (2) RS56015B1 (es)
RU (1) RU2662223C2 (es)
SG (2) SG10201706206PA (es)
SI (2) SI2953931T1 (es)
TW (2) TWI655187B (es)
UA (1) UA120589C2 (es)
UY (1) UY35288A (es)
WO (1) WO2014120808A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2586213T3 (es) 2011-10-31 2016-10-13 Xenon Pharmaceuticals Inc. Compuestos de bencenosulfonamida y su uso como agentes terapéuticos
RU2014121983A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Биарильные простоэфирные сульфонамиды и их применение в качестве терапевтических средств
TW201400446A (zh) 2012-05-22 2014-01-01 Genentech Inc Ｎ－取代之苯甲醯胺及其使用方法
CA2878478A1 (en) 2012-07-06 2014-01-09 Genentech, Inc. N-substituted benzamides and methods of use thereof
KR102295748B1 (ko) 2013-01-31 2021-09-01 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 피리돈 아미드
CN105073738B (zh) 2013-01-31 2018-01-05 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹喔啉酰胺类
MX2015011436A (es) 2013-03-14 2016-06-06 Genentech Inc Triazolopiridinas sustituidas y metodos para usarlas.
WO2014144545A2 (en) 2013-03-15 2014-09-18 Genentech, Inc. Substituted benzoxazoles and methods of use thereof
GEP20207102B (en) 2013-07-19 2020-05-11 Vertex Pharma Sulfonamides as modulators of sodium channels
CN105793238B (zh) 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
MX2017014715A (es) 2015-05-22 2018-03-16 Genentech Inc Benzamidas sustituidas y metodos para utilizarlas.
WO2017035271A1 (en) 2015-08-27 2017-03-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
WO2017058821A1 (en) 2015-09-28 2017-04-06 Genentech, Inc. Therapeutic compounds and methods of use thereof
JP2018535234A (ja) 2015-11-25 2018-11-29 ジェネンテック， インコーポレイテッド ナトリウムチャネル遮断薬として有用な置換ベンズアミド
EP3416947A1 (en) 2016-02-15 2018-12-26 CeMM - Forschungszentrum für Molekulare Medizin GmbH Taf1 inhibitors for the therapy of cancer
US20170239183A1 (en) * 2016-02-23 2017-08-24 PixarBio Corporation COMPOSITIONS COMPRISING NAv1.7 SELECTIVE INHIBITORS FOR TREATING ACUTE, POST-OPERATIVE, OR CHRONIC PAIN AND METHODS OF USING THE SAME
EP3436432B1 (en) 2016-03-30 2021-01-27 Genentech, Inc. Substituted benzamides and methods of use thereof
MA46546A (fr) 2016-10-17 2021-05-05 Genentech Inc Composés thérapeutiques et leurs procédés d'utilisation
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
JP7104070B2 (ja) * 2017-05-16 2022-07-20 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルの調節因子としての重水素化ピリドンアミドおよびそのプロドラッグ
MA49566A (fr) 2017-07-11 2020-05-20 Vertex Pharma Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
JP2021512935A (ja) 2018-02-12 2021-05-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 疼痛を処置する方法
JP2021514980A (ja) 2018-02-26 2021-06-17 ジェネンテック， インコーポレイテッド 疼痛及び関連病態に対するピリジン−スルホンアミド化合物及びその使用
WO2019191702A1 (en) 2018-03-30 2019-10-03 F. Hoffmann-La Roche Ag Substituted hydro-pyrido-azines as sodium channel inhibitors
GEP20237568B (en) 2018-11-02 2023-11-27 Merck Sharp & Dohme Llc 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors
BR112021012909A2 (pt) * 2019-01-04 2021-09-14 Jiangsu Hengrui Medicine Co., Ltd. Derivado de 6-oxo-1,6-di-hidropiridazina, método de preparação do mesmo e uso médico do mesmo
WO2020146682A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
TW202043200A (zh) * 2019-01-25 2020-12-01 大陸商江蘇恆瑞醫藥股份有限公司 ２－側氧基－１，２－二氫吡啶類衍生物、其製備方法及其在醫藥上的應用
BR112021014178A2 (pt) * 2019-02-20 2021-09-21 Jiangsu Hengrui Medicine Co., Ltd. Derivado de pró-fármaco de 6-oxo-1,6-diidropiridazina, método de preparação para o mesmo e aplicação do mesmo na medicina
WO2020176763A1 (en) 2019-02-27 2020-09-03 Vertex Pharmaceuticals Incorporated Dosage form comprising prodrug of na 1.8 sodium channel inhibitor
WO2020219867A1 (en) 2019-04-25 2020-10-29 Vertex Pharmaceuticals Incorporated Pyridone amide co-crystal compositions for the treatment of pain
WO2021018165A1 (zh) * 2019-07-30 2021-02-04 江苏恒瑞医药股份有限公司 吡啶苯甲酰胺类衍生物、其制备方法及其在医药上的应用
CN112390745B (zh) * 2019-08-19 2022-10-21 江苏恒瑞医药股份有限公司 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用
WO2021032074A1 (zh) * 2019-08-19 2021-02-25 江苏恒瑞医药股份有限公司 苯甲酰胺稠芳环类衍生物、其制备方法及其在医药上的应用
CN113906013B (zh) * 2019-09-12 2024-03-12 上海济煜医药科技有限公司 吡啶氮氧化合物及其制备方法和用途
AR120680A1 (es) 2019-12-06 2022-03-09 Vertex Pharma Tetrahidrofuranos sustituidos como moduladores de canales de sodio
CN113045487A (zh) * 2019-12-27 2021-06-29 明慧医药（上海）有限公司 一种选择性钠通道调节剂及其制备和应用
CN114437062B (zh) * 2020-04-30 2024-05-17 成都海博为药业有限公司 一种可作为钠通道调节剂的化合物及其用途
US11802122B2 (en) 2020-06-17 2023-10-31 Merck Sharp & Dohme Llc 2-oxoimidazolidine-4-carboxamides as NAv1.8 inhibitors
CN113880771B (zh) * 2020-07-03 2023-09-19 福建盛迪医药有限公司 一种选择性Nav抑制剂的结晶形式及其制备方法
CN111808019B (zh) * 2020-09-08 2020-11-27 上海济煜医药科技有限公司 一种并环化合物及其应用
CN114031518B (zh) 2020-12-08 2023-08-18 成都海博为药业有限公司 一种苄胺或苄醇衍生物及其用途
BR112023023239A2 (pt) 2021-05-07 2024-01-23 Merck Sharp & Dohme Llc Carboxamidas de cicloalquil 3-oxopiperazina e carboxamidas de cicloheteroalquil 3-oxopiperazina como inibidores de nav1.8
EP4347584A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
WO2022256702A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
WO2022256622A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
EP4347033A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
EP4347583A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
EP4346818A1 (en) 2021-06-04 2024-04-10 Vertex Pharmaceuticals Incorporated Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide
AR126669A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
AR126670A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
WO2023160509A1 (zh) * 2022-02-25 2023-08-31 中国科学院上海药物研究所 脒类衍生化合物及其制备方法和用途
WO2023205778A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205463A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205465A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023207949A1 (zh) * 2022-04-25 2023-11-02 中国科学院上海药物研究所 并环类化合物及其应用
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH598252A5 (es) 1974-01-04 1978-04-28 Hoffmann La Roche
GB1447583A (en) * 1974-02-04 1976-08-25 Ici Ltd Xanthene derivatives
US4086350A (en) * 1974-11-06 1978-04-25 Smithkline Corporation Pharmaceutical compositions and method of producing anti-psychotic activity without extrapyramidal symptoms
GB1543964A (en) * 1976-04-08 1979-04-11 Ici Ltd Method of antagonising herbicides on soyabean and cotton
US5281620A (en) * 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
JP3285391B2 (ja) * 1992-09-01 2002-05-27 日本化学工業株式会社 ２−フェノキシ安息香酸の製造法
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
WO2001021652A1 (en) 1999-09-24 2001-03-29 The Johns Hopkins University School Of Medicine Methods for identifying an agent that corrects defective protein folding
JP2003034671A (ja) * 2001-05-17 2003-02-07 Nippon Nohyaku Co Ltd ベンズアミド誘導体及び農園芸用薬剤並びにその使用方法
KR100705519B1 (ko) * 2002-02-14 2007-04-10 파마시아 코포레이션 Ｐ３８ ｍａｐ 키나제의 조절제로서의 치환된 피리디논
JP2007501804A (ja) * 2003-08-08 2007-02-01 バーテックス　ファーマシューティカルズ　インコーポレイテッド 電位開口型のナトリウムチャネルのインヒビターとして有用な組成物
AP2006003534A0 (en) * 2003-09-03 2006-04-30 Pfizer Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists.
EA200700099A1 (ru) 2004-07-23 2007-08-31 Пфайзер Инк. Производные пиридина
EP1888547A1 (en) 2005-06-09 2008-02-20 Vertex Pharmaceuticals, Inc. Indane derivatives as modulators of ion channels
NZ567132A (en) 2005-09-09 2011-12-22 Vertex Pharma Bicyclic derivatives as modulators of voltage gated ion channels
AU2006304283B2 (en) 2005-10-12 2012-01-19 Vertex Pharmaceuticals Incorporated Biphenyl derivatives as modulators of voltage gated ion channels
US8841483B2 (en) 2006-04-11 2014-09-23 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
ES2398606T3 (es) * 2007-05-03 2013-03-20 Pfizer Limited Derivados de 2-piridin-carboxamida como moduladores de los canales de sodio
CA2687764A1 (en) 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
JP5436434B2 (ja) * 2007-10-11 2014-03-05 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なアミド
CA2701946A1 (en) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
JP5562859B2 (ja) * 2007-10-11 2014-07-30 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なアリールアミド
WO2009058299A1 (en) * 2007-10-31 2009-05-07 Merck & Co., Inc. P2x3 receptor antagonists for treatment of pain
MX2011006843A (es) 2008-12-23 2011-08-04 Hoffmann La Roche Dihidropiridona-amidas como moduladores de p2x7.
US9101616B2 (en) * 2009-05-29 2015-08-11 Raqualia Pharma Inc. Aryl substituted carboxamide derivatives as calcium or sodium channel blockers
AR077033A1 (es) * 2009-06-11 2011-07-27 Hoffmann La Roche Compuestos inhibidores de las quinasas de janus y su uso en el tratamiento de enfermedades inmunologicas
US8883782B2 (en) 2010-03-15 2014-11-11 Amgen Inc. Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use
HUE028983T2 (en) 2010-05-06 2017-01-30 Vertex Pharma Heterocyclic chromene-spirocyclic piperidine amides as ion channel modulators
US8999967B2 (en) 2010-09-29 2015-04-07 Presidio Pharmaceuticals, Inc. Tricyclic fused ring inhibitors of hepatitis C
RS54785B1 (sr) 2011-02-02 2016-10-31 Vertex Pharma Pirolopirazin-spirociklični piperidin amidi kao modulatori jonskih kanala
US8962859B2 (en) 2011-02-15 2015-02-24 Amgen Inc. Spiro-amino-imidazo-fused heterocyclic compounds as beta-secretase modulators and methods of use
JP5940562B2 (ja) 2011-02-18 2016-06-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ イオンチャネルのモジュレーターとしてのクロマン−スピロ環式ピペリジンアミド
ES2618929T3 (es) 2011-03-14 2017-06-22 Vertex Pharmaceuticals Incorporated Morfolina-Spiro piperidina amida cíclica como moduladores del canal iónico
WO2012122716A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
EA025572B1 (ru) 2011-03-29 2017-01-30 Санофи Лекарственные формы отамиксабана с улучшенной стабильностью
WO2013021535A1 (ja) 2011-08-10 2013-02-14 三菱電機株式会社 誘導加熱調理器及びそのプログラム
CN102584774B (zh) 2011-12-22 2014-08-06 合肥工业大学 一种呫吨酮类衍生物及其用途
AU2013229173B2 (en) 2012-03-06 2017-06-01 Pfizer Inc. Macrocyclic derivatives for the treatment of proliferative diseases
CN102659628B (zh) 2012-04-26 2014-07-02 四川大学 含芳酰胺的邻苯二甲腈单体及其合成方法和用其固化制备的聚邻苯二甲腈树脂
WO2014120820A1 (en) 2013-01-31 2014-08-07 Vertex Pharmaceuticals Incorporated Amides as modulators of sodium channels
TWI606048B (zh) 2013-01-31 2017-11-21 帝人製藥股份有限公司 唑苯衍生物
CN105073738B (zh) 2013-01-31 2018-01-05 沃泰克斯药物股份有限公司 作为钠通道调节剂的喹啉及喹喔啉酰胺类
KR102295748B1 (ko) * 2013-01-31 2021-09-01 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 피리돈 아미드
GEP20207102B (en) 2013-07-19 2020-05-11 Vertex Pharma Sulfonamides as modulators of sodium channels
LT3080134T (lt) 2013-12-13 2018-11-12 Vertex Pharmaceuticals Incorporated Piridono amidų provaistai, naudotini kaip natrio kanalų moduliatoriai
MA49566A (fr) 2017-07-11 2020-05-20 Vertex Pharma Carboxamides utilisés en tant qu'inhibiteurs des canaux sodiques
JP2021512935A (ja) 2018-02-12 2021-05-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 疼痛を処置する方法

Also Published As

Publication number Publication date
KR102227592B1 (ko) 2021-03-15
WO2014120808A9 (en) 2015-05-14
US10087143B2 (en) 2018-10-02
HRP20170787T1 (hr) 2017-08-11
US9758483B2 (en) 2017-09-12
SI3239134T1 (sl) 2021-03-31
MX2015009602A (es) 2015-11-25
PH12015501661A1 (en) 2015-10-19
HK1217693A1 (zh) 2017-01-20
TW201443019A (zh) 2014-11-16
IL240195A0 (en) 2015-09-24
CN105026373A (zh) 2015-11-04
PT2953931T (pt) 2017-06-14
CN108164457A (zh) 2018-06-15
HK1244269A1 (zh) 2018-08-03
UA120589C2 (uk) 2020-01-10
SI2953931T1 (sl) 2017-08-31
RU2018126184A3 (es) 2021-07-26
TWI655187B (zh) 2019-04-01
PL2953931T3 (pl) 2017-09-29
US11673864B2 (en) 2023-06-13
US20180016235A1 (en) 2018-01-18
US20150246028A1 (en) 2015-09-03
US10738009B2 (en) 2020-08-11
JP6741704B2 (ja) 2020-08-19
LT2953931T (lt) 2017-07-25
JP2016506963A (ja) 2016-03-07
RS56015B1 (sr) 2017-09-29
AU2014212509B2 (en) 2018-05-10
AU2018214105B9 (en) 2020-04-23
DK3239134T3 (da) 2021-02-22
US20210047271A1 (en) 2021-02-18
JP2019089861A (ja) 2019-06-13
CN105026373B (zh) 2018-03-30
RU2662223C2 (ru) 2018-07-25
US20140213616A1 (en) 2014-07-31
AP2015008633A0 (en) 2015-07-31
AU2018214105B2 (en) 2020-04-02
EP2953931A1 (en) 2015-12-16
JP2021001232A (ja) 2021-01-07
AU2014212509A1 (en) 2015-08-06
AU2020204425A1 (en) 2020-07-23
GEAP201414909A (es) 2020-07-10
HUE033370T2 (en) 2017-11-28
EP3239134B1 (en) 2020-12-23
US20170037009A1 (en) 2017-02-09
WO2014120808A8 (en) 2015-09-11
KR102295748B1 (ko) 2021-09-01
CY1119163T1 (el) 2018-02-14
TWI714967B (zh) 2021-01-01
WO2014120808A1 (en) 2014-08-07
ES2857687T3 (es) 2021-09-29
GEP20207177B (en) 2020-11-10
RU2018126184A (ru) 2019-03-12
BR112015018289A2 (pt) 2017-07-18
PT3239134T (pt) 2021-01-28
EP3865475A1 (en) 2021-08-18
US20190248745A1 (en) 2019-08-15
HRP20210349T1 (hr) 2021-04-16
UY35288A (es) 2014-08-29
PE20191495A1 (es) 2019-10-21
CL2015002147A1 (es) 2016-06-03
RU2015136795A (ru) 2017-03-10
CA2898866A1 (en) 2014-08-07
US9051270B2 (en) 2015-06-09
CN108164457B (zh) 2021-07-09
CA2898866C (en) 2023-03-07
PE20151781A1 (es) 2015-12-02
EP2953931B1 (en) 2017-03-01
JP2018104453A (ja) 2018-07-05
PH12015501661B1 (en) 2015-10-19
US9393235B2 (en) 2016-07-19
ES2626555T3 (es) 2017-07-25
NZ750187A (en) 2020-09-25
RS61503B1 (sr) 2021-03-31
SG10201706206PA (en) 2017-08-30
SG11201505953TA (en) 2015-08-28
KR20210029848A (ko) 2021-03-16
AR094667A1 (es) 2015-08-19
GEP20217286B (en) 2021-08-25
NZ710270A (en) 2020-09-25
AU2018214105A1 (en) 2018-08-30
EP3239134A1 (en) 2017-11-01
TW201943701A (zh) 2019-11-16
PL3239134T3 (pl) 2021-06-14
LT3239134T (lt) 2021-02-25
JP6389194B2 (ja) 2018-09-12
DK2953931T3 (en) 2017-06-06
HUE053448T2 (hu) 2021-06-28
KR20150112031A (ko) 2015-10-06
IL240195B (en) 2019-10-31

Similar Documents

Publication Publication Date Title
PH12015501661A1 (en) Pyridone amides as modulators of sodium channels
MX2015009591A (es) Amidas como moduladores de canales de sodio.
NZ710111A (en) Quinoline and quinoxaline amides as modulators of sodium channels
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
PH12016501028A1 (en) Prodrugs of pyridone amides useful as modulators of sodium channels
MX2019013574A (es) Amidas de piridona deuteradas y sus profarmacos como moduladores de los canales de sodio.
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
MX2013008902A (es) Pirrolopirazina-piperidina espirociclica-amidas como moduladores de canales de ionicos.
PH12015501740A1 (en) Sodium channel modulators for the treatment of pain
IN2015DN01156A (es)
MX2013009393A (es) Piperidinamidas cromano-espirociclicas como moduladores de canales de iones.
MX347982B (es) Morfolina-piperidina espirociclica-amidas como moduladores de canales ionicos.
MX2014008591A (es) Piperidinamidas piranoespirociclicas como moduladores de canales de iones.
IN2014DN10386A (es)
MX2016000038A (es) Amidas de piperidina fusionadas como moduladores de canales de iones.
MX2017004950A (es) Composiciones y metodos para tratar el insomnio.
MY173573A (en) Pyridin-4-yl derivatives
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
EA201992719A1 (ru) Дейтерированные пиридонамиды и их пролекарства в качестве модуляторов натриевых каналов
EA202090268A1 (ru) Карбоксамиды в качестве модуляторов натриевых каналов